TO THE EDITOR:

Inhibitory antibodies (inhibitors) against factor VIII (FVIII) develop in 25% to 35% of previously untreated patients (PUPs) with severe hemophilia A (SHA). It is the most serious complication of classic hemophilia treatment.1-3  Most inhibitors develop during the first 50 exposure days (EDs) to FVIII, with 50% of inhibitors already present after 14 to 15 EDs.2-4  After 50 EDs, inhibitor development is rare and is reported in number of new inhibitors per 1000 person-years. A recent systematic review reported an overall inhibitor incidence of 2.06 per 1000 person-years. A definition specifically designed to separate a priori high-risk and low-risk category patients was established after the outbreaks of 2 product-specific inhibitors in the 1990s.6-8  According to this definition, previously treated patients (PTPs), considered tolerant to exogenous FVIII, are patients with >150 EDs.

Hemophilia treatment has...

REFERENCES

REFERENCES
1.
Calvez
T
,
Chambost
H
,
d’Oiron
R
, et al
; for FranceCoag Collaborators.
Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A
.
Haematologica
.
2018
;
103
(
1
):
179
-
189
.
2.
Gouw
SC
,
van den Berg
HM
,
Fischer
K
, et al
; PedNet and Research of Determinants of INhibitor development (RODIN) Study Group.
Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study
.
Blood
.
2013
;
121
(
20
):
4046
-
4055
.
3.
Iorio
A
,
Halimeh
S
,
Holzhauer
S
, et al
.
Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review
.
J Thromb Haemost
.
2010
;
8
(
6
):
1256
-
1265
.
4.
Fischer
K
,
Lassila
R
,
Peyvandi
F
, et al
; EUHASS participants.
Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project
.
Thromb Haemost
.
2015
;
113
(
5
):
968
-
975
.
5.
Hassan
S
,
Cannavò
A
,
Gouw
SC
,
Rosendaal
FR
,
van der Bom
JG
.
Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review
.
J Thromb Haemost
.
2018
;
16
(
6
):
1055
-
1068
.
6.
White
GC
II
,
Rosendaal
F
,
Aledort
LM
,
Lusher
JM
,
Rothschild
C
,
Ingerslev
J
; Factor VIII and Factor IX Subcommittee.
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis
.
Thromb Haemost
.
2001
;
85
(
3
):
560
.
7.
Rosendaal
FR
,
Nieuwenhuis
HK
,
van den Berg
HM
, et al
; Dutch Hemophilia Study Group.
A sudden increase in factor VIII inhibitor development in multitransfused hemophilia A patients in The Netherlands
.
Blood
.
1993
;
81
(
8
):
2180
-
2186
.
8.
European Medicines Agency
.
Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products.
https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-revision-2_en.pdf. Accessed 14 June 2019.
9.
Arruda
VR
,
Doshi
BS
,
Samelson-Jones
BJ
.
Novel approaches to hemophilia therapy: successes and challenges
.
Blood
.
2017
;
130
(
21
):
2251
-
2256
.
10.
Nilsson
IM
,
Berntorp
E
,
Löfqvist
T
,
Pettersson
H
.
Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B
.
J Intern Med
.
1992
;
232
(
1
):
25
-
32
.
11.
Nijdam
A
,
Altisent
C
,
Carcao
MD
, et al
; PedNet and CANAL study groups.
Bleeding before prophylaxis in severe hemophilia: paradigm shift over two decades
.
Haematologica
.
2015
;
100
(
3
):
e84
-
e86
.
12.
Fischer
K
,
Ljung
R
,
Platokouki
H
, et al
.
Prospective observational cohort studies for studying rare diseases: the European PedNet Haemophilia Registry
.
Haemophilia
.
2014
;
20
(
4
):
e280
-
e286
.
13.
Gouw
SC
,
van der Bom
JG
,
Auerswald
G
,
Ettinghausen
CE
,
Tedgård
U
,
van den Berg
HM
.
Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study
.
Blood
.
2007
;
109
(
11
):
4693
-
4697
.
14.
Marcucci
M
,
Mancuso
ME
,
Santagostino
E
, et al
.
Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis
.
Thromb Haemost
.
2015
;
113
(
5
):
958
-
967
.
15.
McMillan
CW
,
Shapiro
SS
,
Whitehurst
D
,
Hoyer
LW
,
Rao
AV
,
Lazerson
J
.
The natural history of factor VIII:C inhibitors in patients with hemophilia A: a national cooperative study. II. Observations on the initial development of factor VIII:C inhibitors
.
Blood
.
1988
;
71
(
2
):
344
-
348
.
16.
Kempton
CL
,
Soucie
JM
,
Abshire
TC
.
Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates
.
J Thromb Haemost
.
2006
;
4
(
12
):
2576
-
2581
.
17.
Xi
M
,
Makris
M
,
Marcucci
M
,
Santagostino
E
,
Mannucci
PM
,
Iorio
A
.
Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression
.
J Thromb Haemost
.
2013
;
11
(
9
):
1655
-
1662
.
18.
Peyvandi
F
,
Mannucci
PM
,
Garagiola
I
, et al
.
A randomized trial of factor VIII and neutralizing antibodies in hemophilia A
.
N Engl J Med
.
2016
;
374
(
21
):
2054
-
2064
.
19.
Wight
J
,
Paisley
S
.
The epidemiology of inhibitors in haemophilia A: a systematic review
.
Haemophilia
.
2003
;
9
(
4
):
418
-
435
.
20.
Keipert
C
,
Jonker
CJ
,
van den Berg
HM
,
Hilger
A
.
Clinical trials and registries in haemophilia: opponents or collaborators? Comparison of PUP data derived from different data sources
.
Haemophilia
.
2018
;
24
(
3
):
420
-
428
.
You do not currently have access to this content.